Does Rinvoq Help Eczema?
Rinvoq (upadacitinib) treats moderate to severe atopic dermatitis (eczema) in adults and children 12 years and older weighing at least 40 kg whose condition did not respond to other systemic treatments. It reduces inflammation by blocking Janus kinase (JAK) enzymes, leading to clearer skin and less itching.[1][2]
Clinical trials showed 36-70% of patients achieved clear or almost clear skin after 16 weeks on 15 mg or 30 mg daily doses, compared to 8-13% on placebo. Itch relief often starts within the first week.[2][3]
How Rinvoq Compares to Dupixent for Eczema
Rinvoq, an oral JAK inhibitor, works faster on itch than Dupixent (dupilumab), an injectable IL-4/IL-13 blocker. Dupixent clears skin in 30-40% of patients at 16 weeks, but Rinvoq edges it out in rapid symptom control. Both carry black box warnings for serious infections, heart issues, and cancer risk; Rinvoq adds thrombosis and mortality risks.[2][4]
Common Side Effects Patients Report
Upper respiratory infections (20-30%), acne (10-20%), nausea (5-10%), and herpes zoster (3-5%) occur most often. Long-term use raises infection and blood clot risks; avoid live vaccines.[2][5] Patients note quick itch relief but monitor for headaches or elevated cholesterol.
Who Qualifies and When to Start
Prescribed after failing topical treatments or phototherapy. Not for mild eczema or first-line use. Screen for tuberculosis and hepatitis before starting.[1][2]
Rinvoq Dosage and Cost for Eczema
15 mg once daily standard; 30 mg for inadequate response. Annual U.S. cost exceeds $70,000 without insurance; patient assistance programs cut it to $5-25/month for eligible users.[6]
Patent Status and When Generics Might Arrive
AbbVie's key U.S. patents on Rinvoq expire in 2033, with pediatric extensions possible to 2037. No generics until then, though challenges are ongoing.[7]
[1]: FDA Label - Rinvoq (https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s009lbl.pdf)
[2]: Rinvoq.com - Atopic Dermatitis (https://www.rinvoq.com/atopic-dermatitis)
[3]: NEJM Trial (2020) (https://www.nejm.org/doi/full/10.1056/NEJMoa1911860)
[4]: Dupixent.com Comparison Data (https://www.dupixent.com/)
[5]: Drugs.com Side Effects (https://www.drugs.com/sfx/rinvoq-side-effects.html)
[6]: GoodRx Pricing (https://www.goodrx.com/rinvoq)
[7]: DrugPatentWatch.com - Rinvoq Patents (https://www.drugpatentwatch.com/p/tradename/RINVOQ)